Apyx Medical Corporation · NASDAQ:APYX
Apyx Medical — Investor Presentation (May 2026)
18 slides from Apyx Medical's investor presentation, May 2026
Slide 1: Investor Presentation: The Leader in Surgical Aesthetics
INVESTOR PRESENTATION THE LEADER IN SURGICAL AESTHETICS May 2026
Slide 2: Cautionary Statements
CAUTIONARY STATEMENTS Forward Looking Statements Certain matters discussed in this presentation and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Fe
Slide 3: The Leader in Surgical Aesthetics
THE LEADER IN SURGICAL AESTHETICS Real Patients, Real Results ▲ Leading developer of surgical technologies used in minimally invasive aesthetic surgical procedures and ▲ Uniquely positioned to address rapid shifts in market following broad adoption of GLP-1 drugs for weight loss ▲ Renuvion® is the o
Slide 4: Market Trends + Macro Signals
MARKET TRENDS + MACRO SIGNALS Apyx is uniquely positioned to lead the surgical aesthetics market and capture the growing post-weight-loss demand Market Trends Procedural Shifts Consumer Behavior • GLP-1 therapies expected to exceed • Liposuction procedures declined 10.7% • 72% of GLP-1 users report
Slide 5: Multi Billion Dollar Global Market Opportunity
MULTI BILLION DOLLAR GLOBAL MARKET OPPORTUNITY Generators ~$2.3B1 Generators ~$8.5B3 Market opportunity in U.S. Market opportunity worldwide Handpieces ~$750M2 Handpieces ~$1.9B4 Annual market opportunity in U.S. Annual market opportunity worldwide ~15,000 Total estimated Plastic surgeons, cosmetic
Slide 6: Renuvion Single-Use Handpieces – Recurring Revenue
RENUVION SINGLE-USE HANDPIECES – RECURRING REVENUE Growth Driver over past year Single-use handpiece sales account for approximately 50% of revenue for the Surgical Aesthetics business segment in 2025 Current handpiece usages averages approximately 3 per month 6
Slide 7: How Renuvion Works
HOW RENUVION Handpiece inserted WORKS sub-dermally Renuvion® utilizes a unique combination of helium plasma and proprietary radiofrequency Contract skin via direct energy applied via a single-use heating wand inserted under the skin. The energy contracts collagen fibers, pulling the skin closer to t
Slide 8: Real Results
REAL RESULTS PATIENT 51-YEAR-OLD MALE PROCEDURE TYPE LIPOSUCTION + RENUVION® AMOUNT OF FAT REMOVED 100 ml BEFORE 5.5 MONTHS POST-OP* Photos courtesy of Grant Hamlet, MD. *Patient gained 14 lbs since initial procedure 8
Slide 9: Real Results
REAL RESULTS PATIENT BACK CASE EXAMPLE #1 33-YEAR-OLD FEMALE PROCEDURE TYPE LIPOSUCTION + RENUVION® AMOUNT OF FAT REMOVED 1,750 cc BEFORE 2.5 MONTHS POST-OP Photos courtesy of J Kevin Duplechain, MD. Disclosure: The patient shown in the pictures above is an employee of Apyx Medical. 9
Slide 10: AYON: Revolutionizing Body Contouring
AYON: REVOLUTIONIZING BODY CONTOURING Precise, Superior Results: All-in-One Platform: AYON’s integrated Lipo Intelligent Frequency AYON seamlessly integrates Ultrasound-Assisted Tracking (LIFT) Technology offers real-time Liposuction (UAL), Power Liposuction, Renuvion, energy adjustments, ensuring o
Slide 11: Driving Patient Demand + Optimizing Provider Results
DRIVING PATIENT DEMAND + OPTIMIZING PROVIDER RESULTS Renuvion DTC & Physician Marketing Strategy INFLUENCER AMPLIFY AWARNESS ADRESSING THE LOOSE PRACTICE GROWTH + MARKETING IMPACT THROUGH KEY EVENTS SKIN EPIDEMIC ENHANCING RESULTS Leveraging partnerships with Participating in premier lifestyle Launc
Slide 12: Global Presence
GLOBAL PRESENCE Driving Driving growth growth byby expanding expanding customerbase customer baseand andincreasing increasing utilization from existing accounts utilization from existing accounts Sofia, Bulgaria Manufacturing facility We are also registered to sell our We are also registered to sell
Slide 13: 2026 Financial Guidance Upward Revision
2026 FINANCIAL GUIDANCE UPWARD REVISION ▲ Total revenue in the range of $59.0 million to $60.0 million, up from the previous guidance of $57.5 million to $58.5 million. This is compared with $52.8 million reported for the year ended December 31, 2025. • Total revenue guidance assumes: − Surgical Aes
Slide 14: 2025 Company Objectives
2025 COMPANY OBJECTIVES 01 04 Continue to execute commercial launch of AYON Continue to expand library of clinical evidence and capitalize on increased demand for market supporting the use of our Surgical Aesthetic tailwinds related to GLP-1 drugs products 02 05 Continue to expand adoption of Renuvi
Slide 15: Q&A Office Locations
Q&A Office Locations APYX MEDICAL CORPORATION 5115 Ulmerton Road • Clearwater, FL 33760-4004 • USA APYX BULGARIA Manufacturing Facility and European Authorized Service Center 15
Slide 16: Compelling Clinical and Real-World Evidence
COMPELLING CLINICAL AND REAL-WORLD EVIDENCE The safety and efficacy of Renuvion is supported by more than 100 published clinical papers, abstracts and posters, as well as 2 multi-site IDE clinical studies. 16 Clinical Publications at: https://physicians.renuvion.com/library/
Slide 17: Beneath the Surface
BENEATH THE SURFACE CUTTING-EDGE 3-IN-1 ENERGY SYSTEM: RENUVION® ENERGY AND FULL MONOPOLAR AND BIPOLAR FUNCTIONALITY INNOVATIVE FEATURES Adaptive home screen CLOUD Intuitive touch screen CONNECTIVITY Presets by area Procedural information ADVANCED recording and reporting GAS SYSTEM Remote system dia
Slide 18: Strategic Initiatives Announced in Q4 2024 – Value Creation in 2025 Carried in 2026
STRATEGIC INITIATIVES ANNOUNCED IN Q4 2024 – VALUE CREATION IN 2025 CARRIED IN 2026 ▲ Completed a registered direct offering with net proceeds of $7.0 million with a healthcare-focused fund ▲ Amended credit agreement with Perceptive Credit Holdings IV, LP ▲ Significantly reduce the trailing twelve-m